ArticleAdvanced healthcare materials2018
Enhancing Osteosarcoma Killing and CT Imaging Using Ultrahigh Drug Loading and NIR-Responsive Bismuth Sulfide@Mesoporous Silica Nanoparticles.
Article in Advanced healthcare materials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- NIR light-assisted phototherapies for bone-related diseases and bone tissue regeneration: A systematic review.Theranostics · 2020Pooled it
- Radiotherapy-chemodynamic cancer therapy using bismuth-based nanoparticles: a synergistic approach for enhanced cancer treatment.RSC advances · 2025Review
- Types of Bone Substitutes and Their Application in Regenerative Medicine: A Systematic Review.Journal of functional biomaterials · 2025Review
- Ultrasmall Bi/BiNanoscale advances · 2025Article
- Bioinspired nanomedicines for the management of osteosarcoma: Recent progress and perspectives.Materials today. Bio · 2025Review
- Dual-organelle targeted photosensitizer with AIE characteristics for triple-negative breast cancer photodynamic therapy via apoptosis and immunogenic cell death.Materials today. Bio · 2025Article
- Small cell osteosarcoma in gnathic bones in the maxilla: case report in a pediatric patient.Journal of cancer research and clinical oncology · 2025Article
- Role of vascular endothelium and exosomes in cancer progression and therapy (Review).International journal of oncology · 2025Review
- Nanotechnology-Driven Strategies in Osteosarcoma Advances in Treatment: Immunotherapy and Drug Delivery.International journal of nanomedicine · 2025Review
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Non-invasive fast assessment of hepatic injury through computed tomography imaging with renal-clearable Bi-DTPA dimeglumine.Regenerative biomaterials · 2024Article
- Multifunctional mesoporous silica nanoparticles for biomedical applications.Signal transduction and targeted therapy · 2023Review
- Application of advanced biomaterials in photothermal therapy for malignant bone tumors.Biomaterials research · 2023Review
- Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma.Orthopaedic surgery · 2023Review
- Microenvironment Restruction of Emerging 2D Materials and their Roles in Therapeutic and Diagnostic Nano-Bio-Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Nanomaterial-assisted theranosis of bone diseases.Bioactive materials · 2023Review
- Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.Journal of nanobiotechnology · 2023Review
- Engineered exosomes from different sources for cancer-targeted therapy.Signal transduction and targeted therapy · 2023Review
- Metal Sulfide Nanoparticles for Imaging and Phototherapeutic Applications.Molecules (Basel, Switzerland) · 2023Review
- Oxidative stress induced by berberine-based mitochondria-targeted low temperature photothermal therapy.Frontiers in chemistry · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Despite its 5-year event-free survival rate increasing to 60-65% due to surgery and chemotherapy, osteosarcoma (OS) remains one of the most threatening malignant human tumors, especially in young patients. Therefore, a new approach that combines early diagnosis with efficient tumor eradication and bioimaging is urgently needed. Here, a new type of mesoporous silica-coated bismuth sulfide nanoparticles (Bi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.